deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 0.75 [0.59; 0.95], 1 RCT, I2=0% conclusive
unassessable degree of certainty